Pharmacogenetics, genomics, proteomics: The new frontiers in drug development

International Journal of Pharmaceutical Medicine

Volumn 13, Issue 4, 1999, Pages 197-202

  Moyses, Chris ^a  

^a Oxford GlycoSciences   (United Kingdom)

Author keywords

Clinical trials; Drug development; Genomics; Pharmacogenomics; Pharmacoproteomics; Proteomics

Indexed keywords

MESSENGER RNA; PRAVASTATIN; SALBUTAMOL;

ASTHMA; CORONARY ARTERY ATHEROSCLEROSIS; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG MONITORING; DRUG RESEARCH; DRUG TARGETING; GENE SEQUENCE; GENETIC PREDISPOSITION; HUMAN; METHODOLOGY; PATHOPHYSIOLOGY; PATIENT SELECTION; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; RNA ANALYSIS;

EID: 0032847892     PISSN: 13649027     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. US National Center for Biotechnology Information Website, Entrez web server; URL: http://www.ncbi.nlm.nih.gov/
2. The C elegans Sequencing Consortium. Genome sequence of the nematode C. elegans: a platform for investigating biology. Science 1998; 282:2012-2018.
3. Gu Z, Hillier L, Kwok PY Single nucleotide polymorphism hunting in cyberspace. Hum Mutat 1998; 12:221-5
4. Milla PJ. Cystic fibrosis: present and future. Digestion 1998; 59:579-88
5. Mayeux R, Saunders AM, Shea S et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. N Engl J Med 1998; 338:506-11
6. Caraco Y. Genetic determinants of drug responsiveness and drug interactions. Ther Drug Monit 1998; 20:517-24
7. Martinez FD, Graves PE, Baldini M et al. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 100:3184-8
8. Kuivenhoven JA, Jukema JW, Zwinderman AH et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med 1998; 338:86-93
9. Persidis A. Pharmacogenomics and diagnostics. Nature Biotechnology 1998; 16:791-792
10. FS. Genetics: an explosion of knowledge is transforming clinical practice. Geriatrics 1999; 54:41-47
11. Housman D, Ledley FD. Why pharmacogenomics? Why now? Nature Biotechnology 1998; 16:492-493
12. Bailey DS, Bondar A, Furness LM. Pharmacogenomics - it's not just pharmacogenetics. Current Opinion in Biotechnology 1998; 9:595-601
13. Risen N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996; 272:1516-1517
14. Chakravarti A. It's raining SNPs, hallelujah. Nature Genetics 1998; 19:216-217
15. Terwilliger JD, Weiss KM. Linkage disequilibrium mapping of complex disease: fantasy or reality? Current Opinion in Biotechnolgy 1998; 9:578-594
16. Pennisi E. A closer look at SNPs suggests difficulties. Science 1998; 281:1787-1789
17. Watson A, Mazumder A, Stewart M, Balasubramanium S. Technology for microarray analysis of gene expression. Current Opinion in Biotechnology 1998; 9:609-614
18. Anderson L, Seilhamer J. Electrophoresis 1997; 18:533-537
19. Persidis A. Proteomics. Nature Biotechnology 1998; 16:393-394
20. Anderson NL, Anderson NG. Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis. 1998; 19:1853-61.
21. A. Profiting from proteomics: strategies and technologies. PJB Publications, London. 1998.
22. Johnson PJ, Poon TCW, Hjelm MN et al. The glycan composition of serum alpha-fetoprotein in patients with hepatocellular carcinoma and non-semi-natomous germ cell tumor. (Submitted for publication)
23. Johnson PJ, Ho S, Welby C et al. Application of proteome analysis to the detection of 'hepatoma specific' serum proteins. Proceedings of the American Association for Cancer Research 1998; 39:238 (abstract).